Date | Title | Description | |
---|---|---|---|
21 Feb 2023 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
21 Feb 2023 | On business and financial situation | The Company releases the full year 2022 financial results presentation. | Download |
23 Nov 2022 | On business and financial situation | The Company releases the presentation related to its strategy update because of its 2022 Capital Markets Day | Download |
04 Nov 2022 | On business and financial situation | The Company releases the press release related to the first nine months of 2022 financial results | Download |
04 Nov 2022 | On business and financial situation | The Company releases the first nine months 2022 financial results presentation | Download |
Pages
Date | Title | Description | |
---|---|---|---|
17 May 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 10 May and 16 May 2024 | Download |
10 May 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 2 May and 9 May 2024 | Download |
08 May 2024 | Announcement of General Shareholders’ Meeting | The Company announces the decision of its Board of Directors to convene the Ordinary General Shareholders' Meeting | Download |
30 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 26 April and 30 April 2024 | Download |
26 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 19 April and 25 April 2024 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
06 Apr 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2017 | Download |
13 Mar 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to its biosimilar of Enoxaparin | Download |
07 Mar 2017 | Otros sobre negocio y situación financiera | ROVI informs that the Decentralised procedure used for the registration of its biosimilar of enoxaparin has been completed with positive outcome | Download |
16 Feb 2017 | Otros sobre Gobierno Corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |
16 Feb 2017 | Informe anual de remuneraciones de los consejeros | ROVI releases the 2016 annual report regarding remuneration of the members of the Board of Directors | Download |